Gubra A/S/DKr GUBRA
1D1W1MYTD1Y5YMAX
Capital at risk
About Gubra A/S
Gubra A/S is a biotechnology company based in Denmark, focusing on pre-clinical contract research and drug discovery. It specializes in the development of peptide-based therapeutics and provides services in areas such as obesity, diabetes, and NASH (non-alcoholic steatohepatitis). The company was founded in 2008 and operates from its headquarters in Hørsholm, Denmark. Gubra differentiates itself through its integrated approach combining histology, imaging, and bioinformatics to deliver comprehensive research services. Its strategic positioning leverages cutting-edge technology to support pharmaceutical companies in early-stage drug development.
- Ticker
- DKr GUBRA
- Sector
- Health
- Primary listing
- CSE
- Employees
- 330
- Headquarters
- Horsholm, Denmark
- Website
- www.gubra.dk
Gubra A/S Metrics
BasicAdvanced
kr 5B
-
-kr 11.16
0.32
-
Price and volume
Market cap
kr 5B
Beta
0.32
52-week high
kr 557.50
52-week low
kr 290.20
Average daily volume
31K
Financial strength
Current ratio
11.424
Quick ratio
10.743
Long term debt to equity
0.151
Total debt to equity
0.178
Interest coverage (TTM)
-2.47%
Profitability
EBITDA (TTM)
-191.652
Gross margin (TTM)
75.29%
Net profit margin (TTM)
-67.25%
Operating margin (TTM)
-73.07%
Effective tax rate (TTM)
-2.50%
Revenue per employee (TTM)
kr 820,000
Management effectiveness
Return on assets (TTM)
-5.89%
Return on equity (TTM)
-16.12%
Valuation
Price to revenue (TTM)
18.262
Price to book
4.75
Price to tangible book (TTM)
4.82
Price to free cash flow (TTM)
-6.207
Free cash flow yield (TTM)
-16.11%
Free cash flow per share (TTM)
-48.815
Growth
Revenue change (TTM)
-89.72%
Earnings per share change (TTM)
-110.49%
3-year revenue growth (CAGR)
10.02%
3-year earnings per share growth (CAGR)
173.82%
Bulls say / Bears say
The initiation of the Phase 1/2a clinical trial of GUB-UCN2 marks a major internal pipeline milestone, positioning Gubra at the forefront of differentiated obesity therapeutics with first human safety and PK data due H1 2027. (Gubra)
Partner Boehringer Ingelheim’s launch of the Phase 2 trial for BI 3034701 triggered a €10 million milestone payment, underscoring the commercial value and validation of Gubra’s peptide-based discovery platform. (Gubra)
Gubra’s CRO business achieved 11% revenue growth versus H2 2025 and stabilized profitability in H1 2026, demonstrating resilient demand and secure cash flow to support biotech R&D investments. (Gubra)
Biotech external revenue plunged 99% YoY to DKK 30 million in H1 2026, highlighting volatile, milestone-driven income that may impair near-term revenue visibility. (Gubra)
The group reported an operating loss of DKK 123 million in H1 2026 despite CRO growth, reflecting ongoing cash burn and potential need for external financing to fund its biotech pipeline. (Gubra)
Initial clinical data for GUB-UCN2 are not expected until H1 2027, extending the timeline to key value inflection points and increasing execution risk over the elongated development period. (Gubra)
Data summarised monthly by Lightyear AI. Last updated on 25 Aug 2026.
Upcoming events
No upcoming events
Funds containing Gubra A/S
AllUSDEURGBP
Fund name | Fund size | DKr GUBRA weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.03% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.03% |
iShares Healthcare Innovation£DRDR | £1B | 0.03% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.02% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.